@dachopper
You are absolutely correct, this is because the NYHA classification is very subjective. See below of an extract from an article:
"The survey of cardiologists showed no consistent method for assessing NYHA class and a literature survey showed that 99% of research papers do not reference or describe their methods for assigning NYHA classes. The interoperator variability study showed only 54% concordance between the two cardiologists."
However, no one can miss diabetic/ischemic classification; furthermore, there seems to be a bidirectional link between diabetes and heart-failure. exert from this article write: "People who have Type 2 diabetes, characterized by elevated blood sugar levels, are two to four times more likely to develop heart failure than someone without diabetes. But heart failure, a condition in which the heart fails to efficiently pump oxygenated blood through the body, also is a risk factor for diabetes"
I also agree with you that our target population for the next trial should be 1) CRP >2 (inflammation), 2) NYHA class II - III (but the study will enriched for class II, as many class III patients have too much scare tissues already in the heart) 3) diabetic/ischemic patients (either as an inclusion criteria OR as a pre-specified subpopulation)
Ideally we would ignore class III patients, but since it is so difficult to discern between class II & III, it is wiser to include both into the next trial, whatever the next trial may be (either another phase 3; or a phase 4 (slim chance)- if we get Accelerated Approval for the diabetic/ischemic group).
The meeting with the FDA will be interesting, because if we have to wait for another phase 3 trial, that's at least 4-5 years before we see any results, during which more patients would have died from HF.
- Forums
- ASX - By Stock
- MSB
- Ann: Biotech Showcase 2022 Presentation
Ann: Biotech Showcase 2022 Presentation, page-14
-
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.09 |
Change
0.060(5.83%) |
Mkt cap ! $1.244B |
Open | High | Low | Value | Volume |
$1.04 | $1.10 | $1.03 | $4.925M | 4.571M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7260 | $1.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 67541 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7260 | 1.090 |
1 | 25000 | 1.085 |
5 | 82706 | 1.080 |
3 | 70397 | 1.075 |
5 | 96320 | 1.070 |
Price($) | Vol. | No. |
---|---|---|
1.095 | 67541 | 7 |
1.100 | 660901 | 37 |
1.105 | 27523 | 3 |
1.110 | 173120 | 11 |
1.115 | 55278 | 5 |
Last trade - 16.10pm 26/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |